TAK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Takeda Pharmaceutical Co Ltd (TAK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite the lack of immediate trading signals, the company's strong financial performance, analyst upgrade, and oversold technical indicators present a solid opportunity for long-term growth.
The MACD is negatively expanding, indicating bearish momentum, but the RSI is at 14.821, signaling an oversold condition. Moving averages are converging, suggesting potential stabilization. The stock is trading near its S2 support level of 16.386, which could act as a strong buying zone.
Analyst upgrade by Bernstein with a significant price target increase, citing cost cuts and pipeline de-risking events.
Strong financial performance in Q3 2026, with a 335.66% YoY increase in net income and a 337.08% YoY increase in EPS.
Oversold RSI indicating potential for a price rebound.
No recent news or event-driven catalysts.
MACD indicates bearish momentum.
Lack of significant hedge fund or insider trading activity.
In Q3 2026, Takeda reported a 4.16% YoY increase in revenue, a 335.66% YoY increase in net income, a 337.08% YoY increase in EPS, and a 5.94% YoY increase in gross margin, showcasing strong growth trends.
Bernstein upgraded Takeda to Outperform from Market Perform with a price target increase from 5,100 yen to 6,900 yen, highlighting bold cost cuts and upcoming pipeline de-risking events.
